- •Compulsive eating was not related to dopaminergic replacement therapy.
- •Other impulse control disorders showed clear relation to dopamine agonist therapy.
- •Punding was associated with higher dose of both dopamine agonists and L-dopa.
- •Rotigotine might cause less ICRBDs than other dopamine agonists.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Journal of the Neurological Sciences
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients.Arch Neurol. 2010; 67 ([Epub 2010/05/12]): 589-595
- Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study.Brain. 2009; 132 ([Epub 2009/04/07]): 1376-1385
- Insights into pathophysiology of punding reveal possible treatment strategies.Mol Psychiatry. 2010; 15 ([Epub 2010/05/22]): 560-573
- Association of dopamine agonist use with impulse control disorders in Parkinson disease.Arch Neurol. 2006; 63 ([Epub 2006/07/13]): 969-973
- Association between the dose of dopaminergic medication and the behavioral disturbances in Parkinson disease.Parkinsonism Relat Disord. 2010; 16 ([Epub 2009/12/19]): 202-207
- Rotigotine in the treatment of Parkinson's disease. A study on a sample of 150 patients.Rev Neurol. 2008; 46 ([Epub 2008/03/21. Rotigotina en el tratamiento de la enfermedad de Parkinson. Experiencia sobre una muestra de 150 pacientes]): 257-260
- The safety and tolerability of rotigotine transdermal system over a 6-year period in patients with early-stage Parkinson's disease.J Neural Transm. 2013; 120 ([Epub 2013/03/20]): 1321-1329
- A novel dopamine agonist for the transdermal treatment of Parkinson's disease.Neurology. 2005; 65 ([Epub 2005/07/21]): S3-S5
- A promising new technology for Parkinson's disease.Neurology. 2005; 65 ([Epub 2005/07/21]): S6-S10
- Punding and dyskinesias.Mov. Disord. 2006; 21 ([Epub 2006/10/03]): 2214-2217
Published online: July 09, 2014
Accepted: July 1, 2014
Received in revised form: May 31, 2014
Received: August 29, 2013
© 2014 Elsevier B.V. Published by Elsevier Inc. All rights reserved.